文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

微针贴片递送灭活流感疫苗的安全性、免疫原性与可接受性(TIV-MNP 2015):一项随机、部分盲法、安慰剂对照的1期试验

The safety, immunogenicity, and acceptability of inactivated influenza vaccine delivered by microneedle patch (TIV-MNP 2015): a randomised, partly blinded, placebo-controlled, phase 1 trial.
PubMed 文献 · Lancet · 2017-06-27

该1期试验将100名18-49岁未接种过2014-15流感疫苗的健康成人随机分四组,分别接受医护人员操作的微针贴片或肌内注射灭活流感疫苗、安慰剂微针贴片、或受试者自用微针贴片。结果显示微针贴片耐受良好,无治疗相关严重不良事件,抗体应答与肌内注射相似,受试者自用可行。

要点

  • 微针贴片接种流感疫苗耐受良好,无治疗相关严重不良事件。
  • 第28天血凝抑制抗体几何平均滴度微针贴片与肌内注射相似。
  • 受试者自用微针贴片可行,抗体应答与医护人员操作相似。

核心结论

  • 使用可溶解微针贴片进行流感疫苗接种耐受良好,并产生稳健的抗体应答。

研究设计与样本

  • TIV-MNP 2015为在埃默里大学开展的随机、部分盲法、安慰剂对照1期临床试验,纳入100名18-49岁未接种2014-15流感疫苗且无显著皮肤病的健康成人,按1:1:1:1随机分四组。

主要发现

  • 无治疗相关严重不良事件、无治疗相关非征集性3级或以上不良事件、无新发慢性病。
  • 接种组(医护人员操作微针贴片、肌内注射、自用微针贴片)征集性不良事件总体发生率(n=89 vs n=73 vs n=73)和非征集性不良事件(n=18 vs n=12 vs n=14)相似。
  • 肌内注射后最常见为压痛(15/25,60%,95%CI 39-79)和疼痛(11/25,44%,95%CI 24-65);微针贴片后为压痛(33/50,66%,95%CI 51-79)、红斑(20/50,40%,95%CI 26-55)和瘙痒(41/50,82%,95%CI 69-91)。
  • 第28天几何平均滴度在医护人员操作微针贴片与肌内注射间相似:H1N1株1197(95%CI 855-1675)vs 997(95%CI 703-1415),p=0.5;H3N2株287(95%CI 192-430)vs 223(95%CI 160-312),p=0.4;B株126(95%CI 86-184)vs 94(95%CI 73-122),p=0.06。
  • 自用微针贴片者几何平均滴度相似(所有p>0.05);第28天血清转化百分比微针贴片显著高于安慰剂(所有p<0.0001),与肌内注射相似(所有p>0.01)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Microneedle patches provide an alternative to conventional needle-and-syringe immunisation, and potentially offer improved immunogenicity, simplicity, cost-effectiveness, acceptability, and safety. We describe safety, immunogenicity, and acceptability of the first-in-man study on single, dissolvable microneedle patch vaccination against influenza. METHODS: The TIV-MNP 2015 study was a randomised, partly blinded, placebo-controlled, phase 1, clinical trial at Emory University that enrolled non-pregnant, immunocompetent adults from Atlanta, GA, USA, who were aged 18-49 years, naive to the 2014-15 influenza vaccine, and did not have any significant dermatological disorders. Participants were randomly assigned (1:1:1:1) to four groups and received a single dose of inactivated influenza vaccine (fluvirin: 18 μg of haemagglutinin per H1N1 vaccine strain, 17 μg of haemagglutinin per H3N2 vaccine strain, and 15 μg of haemagglutinin per B vaccine strain) (1) by microneedle patch or (2) by intramuscular injection, or received (3) placebo by microneedle patch, all administered by an unmasked health-care worker; or received a single dose of (4) inactivated influenza vaccine by microneedle patch self-administered by study participants. A research pharmacist prepared the randomisation code using a computer-generated randomisation schedule with a block size of 4. Because of the nature of the study, participants were not masked to the type of vaccination method (ie, microneedle patch vs intramuscular injection). Primary safety outcome measures are the incidence of study product-related serious adverse events within 180 days, grade 3 solicited or unsolicited adverse events within 28 days, and solicited injection site and systemic reactogenicity on the day of study product administration through 7 days after administration, and secondary safety outcomes are new-onset chronic illnesses within 180 days and unsolicited adverse events within 28 days, all analysed by intention to treat. Secondary immunogenicity outcomes are antibody titres at day 28 and percentages of seroconversion and seroprotection, all determined by haemagglutination inhibition antibody assay. The trial is completed and registered with ClinicalTrials.gov, number NCT02438423. FINDINGS: Between June 23, 2015, and Sept 25, 2015, 100 participants were enrolled and randomly assigned to a group. There were no treatment-related serious adverse events, no treatment-related unsolicited grade 3 or higher adverse events, and no new-onset chronic illnesses. Among vaccinated groups (vaccine via health-care worker administered microneedle patch or intramuscular injection, or self-administered microneedle patch), overall incidence of solicited adverse events (n=89 vs n=73 vs n=73) and unsolicited adverse events (n=18 vs n=12 vs n=14) were similar. Reactogenicity was mild, transient, and most commonly reported as tenderness (15 [60%] of 25 participants [95% CI 39-79]) and pain (11 [44%] of 25 [24-65]) after intramuscular injection; and as tenderness (33 [66%] of 50 [51-79]), erythema (20 [40%] of 50 [26-55]), and pruritus (41 [82%] of 50 [69-91]) after vaccination by microneedle patch application. The geometric mean titres were similar at day 28 between the microneedle patch administered by a health-care worker versus the intramuscular route for the H1N1 strain (1197 [95% CI 855-1675] vs 997 [703-1415]; p=0·5), the H3N2 strain (287 [192-430] vs 223 [160-312]; p=0·4), and the B strain (126 [86-184] vs 94 [73-122]; p=0·06). Similar geometric mean titres were reported in participants who self-administered the microneedle patch (all p>0·05). The seroconversion percentages were significantly higher at day 28 after microneedle patch vaccination compared with placebo (all p<0·0001) and were similar to intramuscular injection (all p>0·01). INTERPRETATION: Use of dissolvable microneedle patches for influenza vaccination was well tolerated and generated robust antibody responses. FUNDING: National Institutes of Health.

来源:Lancet,查看原文。版权归原作者所有。

引用

  1. Rouphael NG, Paine M, Mosley R, et al. The safety, immunogenicity, and acceptability of inactivated influenza vaccine delivered by microneedle patch (TIV-MNP 2015): a randomised, partly blinded, placebo-controlled, phase 1 trial. Lancet. 2017. PMID: 28666680. doi:10.1016/S0140-6736(17)30575-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。